A biotech update on the start of late-stage clinical testing for a metabolic liver therapy, previewing trial aims and development context.
Key Takeaways
- Study will evaluate the safety and efficacy of pemvidutide for metabolic dysfunction-associated steatohepatitis
- Company claims pemvidutide is a balanced 1:1 dual receptor agonist targeting glucagon and GLP-1 receptors
- Pemvidutide is also being investigated for alcohol use disorder and alcohol-associated liver disease